These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 15071956

  • 1. [Gene therapy using retroviral vectors].
    Hanawa H, Shimada T.
    Uirusu; 2003 Dec; 53(2):177-83. PubMed ID: 15071956
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
    Schimmer J, Breazzano S.
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
    [Abstract] [Full Text] [Related]

  • 5. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
    Ylä-Herttuala S.
    Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gene therapy's out-of-body experience.
    Scott CT, DeFrancesco L.
    Nat Biotechnol; 2016 Jun 09; 34(6):600-7. PubMed ID: 27281416
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy.
    Carlucci F, Tabucchi A, Aiuti A, Rosi F, Floccari F, Pagani R, Marinello E.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct 09; 23(8-9):1245-8. PubMed ID: 15571238
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
    Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB.
    Blood; 2012 Nov 01; 120(18):3635-46. PubMed ID: 22968453
    [Abstract] [Full Text] [Related]

  • 14. [Safety of retroviral vectors in gene therapy].
    Bogoslovskaia EV, Glazkova DV, Shipulin GA, Pokrovskiĭ VV.
    Vestn Ross Akad Med Nauk; 2012 Nov 01; (10):55-61. PubMed ID: 23240501
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gene therapy for severe combined immunodeficiencies and beyond.
    Fischer A, Hacein-Bey-Abina S.
    J Exp Med; 2020 Jan 06; 217(2):. PubMed ID: 31826240
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genetic therapy using bone marrow transplantation.
    Giles RE, Hanania EG, Fu S, Deisseroth A.
    Cancer Treat Res; 1995 Jan 06; 76():271-80. PubMed ID: 7577339
    [No Abstract] [Full Text] [Related]

  • 20. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
    Baum C.
    EMBO Mol Med; 2011 Feb 06; 3(2):75-7. PubMed ID: 21254403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.